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BILIRUBIN NANOPARTICLE AS AN ANTI-INFLAMMATORY THERAPY FOR GRAFT
VERSUS HOST DISEASE

Sumedha Pareek, B.Tech., M.Tech.

Advisory Professor: Jin Seon Im, M.D., Ph.D.

Graft versus host disease (GvHD) caused by allore active donor
lymphocytes is a fatal complication of hematopoietic stem cell transplant
(HSCT). Myeloablative conditioning regimen, consisting of chemotherapy and/or
radiation, given prior to HSCT can cause tissue damage. This non-specific tissue
damage triggers cross-presentation of alloantigens to the donor immune cells,
causing recruitment of leukocytes and production of inflammatory cytokines.
Targeting this inflammation without affecting the anti -leukemia effects of HSCT,
continues to be one of the biggest challenge in finding a therapy for GvHD.
Bilirubin is a tetrapyrrole pigment, found in the blood, with natural anti -oxidative
and anti-inflammatory properties. Using mouse models of various inflammatory
diseases, studies by our collaborating investigators have shown that, watersoluble PEGylated bilirubin nanoparticles (BRNP) selectively accumulate at the
site of inflammation and prevent further tissue damage through scavenging
reactive oxygen species. Therefore, we hypothesized that BRNP treatment after
myeloablative conditioning regimen can reduce clinical symptoms of GvHD by
abating the initial tissue damage in HSCT. We investigated the therapeutic
efficacy of BRNP using murine GvHD model. Sublethally irradiated recipient
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mice (Balb/cJ) were infused with 5x10 6 bone marrow cells and 5x10 6 splenic
cells from MHC-mismatched donor mice (C57/B6J) on day 1, with or without
BRNP (10 mg/kg) on days 0-4. Clinical GvHD symptoms were monitored for 60
days, and mice were scored for fur, skin, posture, activity, and weight change.
Untreated recipient mice (n=10) developed significantly worse GvHD (median
GvHD score=3.4) compared to BRNP treated recipient mice (n=10, median
GvHD score=0.3) (p=0.0003, Mann Whitney U Test). This translated into
significantly better survival of BRNP treated mice with day 60 survival of 100%
as compared to the untreated recipient with day 60 survival of 20% (p=0.0001,
Log-rank

(Mantel-Cox)

Test).

Histological

analyses

on

day

8

post-

transplantation, showed significantly lowered GvHD associated damage in liver,
lung, skin, and gut, in BRNP treated mice as compared with untreated mice . In
summary, we show that prophylactic treatment with BRNP can reduce clinical
and pathological GvHD symptoms and thereby improve survival in mice. In
future, we plan to investigate a treatment model of BRNP in relieving the clinical
and pathological symptoms of GvHD. We also plan to explore the potential of
BRNP as a drug conjugate for GvHD treatment.
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Chapter 1- Introduction

1.1 Hematopoietic Stem Cell Transplantation

1.1.1 Hematological Malignancies

Hematological malignancies, also commonly known as blood cancers,
encompass all of cancer subtypes that affect the development and function of
various blood cells. Blood cancers can be divided into three broad categories:
Leukemia- originates in cells found in the blood and the bone marrow;
Lymphoma- originates in the cells found in the lymph nodes; Myeloma - affects
the production and functioning of antibody producing plasma cells. Together, the
three categories of blood cancer, are responsible for approximately 10% of
cancer related deaths in the United States every year (1).
Depending on patient’s age, health, and stage and type of blood cancer,
physician recommends specific treatment options or their combination. The first
line of therapy recommendation for leukemia patients is usually chemotherapy,
which targets the rapidly dividing cancer cells. Acute myeloid leukemia (AML) is
the most common subtype, occurring in almost one-third of the adult patients of
leukemia (1). According to recent statistics by the American Cancer Society,
approximately 90% of patients with an AML subtype - acute promyelocytic
leukemia (APL) and 67% of patients with other subtypes of AML, go into
remission after chemotherapy induction. Despite the high remission rates, recent
reports by the National Cancer Institute show that the overall 5 -year survival
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rates of all AML patients are the lowest among other leukemia subtypes at
28.3%.

Hematopoietic stem cells (HSCs) are unique, self -renewing stem cells that
are also capable of differentiating into all lineages of cells that comprise the
blood- in a process called hematopoiesis. Hematopoiesis starts during
embryonic development and continues into adulthood. Over the last fifty years,
there has been an exponential increase in our knowledge on the biology of HSCs
(2). This breakthrough has led to development of hematopoietic stem cell
transplantation (HSCT) as potentially curative therapy for various hematological
disorders, especially blood cancers. In fact, five -year survival rates for leukemia
in United States, have risen from 14% in the 1960 to 65% in 2014. Among the
total number of allogeneic HSCTs performed around the world, about one-third
are indicated for AML patients (3). According to 2006-2016 statistics by Center
for International Blood and Marrow Transplant Research (CIBMTR), among
approximately 13,000 AML patients, those who received stem cell transplant
from their sibling as donor, had survival rates between 20 -55% depending on
the stage of diagnosis (early, intermediate, or late). These statis tics show that
HSCT offers long-term survival, especially for patients with AML . However,
despite a large number of patients responding to therapy, a majority of the
leukemia patients who do achieve complete remission, go on to relapse (4) or
develop complications such as organ failure, infections, and graft versus host
disease (5).
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1.1.2 Hematopoietic Stem Cell Transplantation

Human hematopoietic system comprises of all the cell types that
constitute the blood, bone marrow, and the lymphatic system. H ematopoietic
stem cell transplantation is one of the most important and potentially curative
therapy for leukemia and other hematological malignancies. Depending on the
disease condition, recommended HSCT can be either autologous, syngeneic, or
allogeneic.

In autologous HSCT, the donor is the patient themselves and it is indicated
for various hematological disorders, as well as cancers. Autologous HSCT is
used to reconstitute hematopoietic system for cancer patients who are given
high-dose chemotherapy and/or radiation. It is recommended as treatment
modality for multiple myeloma, Non-Hodgkin’s lymphoma, Hodgkin’s disease,
acute myeloid leukemia, neuroblastoma, and ovarian cancer (6). It is also
recommended for diseases that do not require the anti-tumor (also known as
graft versus leukemia (GvL) effect) benefits of transplant such as aplastic
anemia and bone marrow diseases, or where tumor response to chemotherapy
is high, such as germ cell tumors (ovarian cancer a nd testicular cancer) (7).
Syngeneic HSCT is similar to autologous HSCT except that the donor is patient’s
twin/triplet. While there is no development of graft versus host disease in
syngeneic HSCT, the anti-cancer benefits are limited to high-dose chemotherapy
(8).

In allogeneic HSCT, the donor is not the patient, but a matched or
mismatched donor. Allogeneic HSCT is indicated for acute myeloid leukemia,
3

acute

lymphoblastic

leukemia,

chronic

myeloid

leukemia,

relapsed

and

refractory Non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, relapsed
and refractory multiple myeloma, and some hematological disorders such as
sickle-cell anemia and Wiskott–Aldrich syndrome. While allogeneic transplant
has high GvL activity, it is often accompanied by inflammation in host tissue due
to donor T-cell alloreactivity in a complication known as graft versus host
disease (GvHD)

Allogeneic HSCT was first attempted in the 1960s, a few years after
human leukocyte antigen (HLA) typing was first discovered (9).The first step in
allogeneic HSCT is to find a human leukocyte antigen-matched donor. HLA is a
gene system that encodes for major histocompatibility complex (MHC) proteins.
The main function of the MHC protein is to present antigen in the form of peptides
to the surveilling immune cells. The cytotoxic T-cells recognize MHC together
with the antigen peptide, in a process known as MHC-restriction. MHC proteins
are highly polymorphic, however one individual can have, at most, 12 different
MHC alleles (10). High-resolution HLA-typing is employed to identify a matched
donor. HLA-A, -B, and –C genes under Class I HLA encode for MHC Class I
protein that is expressed on almost all the nucleated cells in the body. Whereas,
HLA-DP, -DQ, and –DR encode for MHC Class II protein that are expressed only
on professional antigen presenting cells such as the dendritic cells, B -cells, and
monocytes (11). HLA-typing is done for HLA-A, -B, -C and -DRB1 (encodes HLADR β-chain) to find an 8/8 match (a complete match) or a 7/8 match (12). The
allelic diversity in HLA genes across population, makes it difficult to find a
complete match, especially for the minority ethnicities in USA such as the
4

African-Americans (19% likelihood for 8/8 match), Africans (16% likelihood for
8/8 match), as compared to White Europeans (75% likelihood for 8/8 match)
according to the 2014 statistics (13).

After identifying a matched donor, the patient goes through myeloablative
conditioning regimen, which consists of chemotherapy and/or radiation therapy.
Conditioning regimen is given to induce immunosuppression by eliminating all
the patient immune cells including any leukemia cells. Meanwhile, donor
peripheral blood or bone marrow is collected and processed to obtain HSCs,
which are then transplanted to the recipient. Once transplanted, donor HSCs
have two major functions- firstly, to kill any remnant leukemia cells in the
patient’s body or the GvL effect, and secondly, to reconstitute the hematopoietic
system of the patient who has undergone conditioning regimen .

1.2 Graft Versus Host Disease

Allogenic HSCT however, comes with a debilitating side-effect of acute or
chronic graft versus host disease. GvHD is a state of immunological disarray
caused by the donor immune system which results in inflammation and tissue
damage to the host. Since 2005, NIH recommended classification into acute or
chronic GvHD is based on the time of onset of GvHD and the symptoms (14).
Typically, acute GvHD manifests as skin rash, inc reased blood bilirubin levels,
gastrointestinal tract damage leading to nausea, vomiting, diarrhea, and
anorexia (15). It is one of the leading cause of mortality, and some of the
symptoms manifest among most patients that receive allogeneic HSCT (16). It
affects approximately 30-50% and severe acute GvHD occurs in approximately
5

14%, of the patients that receive allogeneic transplant f rom an HLA-matched
donor (11, 15). The current globally immunosuppressive therapies are effective
in treating the symptoms, but may interfere with the GvL effect of allo geneic
HSCT, thereby not reducing post-transplantation mortality (17). Therefore, there
is a growing need to control the potentially lethal effects of GvHD without
affecting GvL activity.

1.2.1 GvHD Signaling Cascade

The process of GvHD development starts with the administration of
conditioning regimen. Conditioning regimen consists of chemotherapy and/or
radiation, which are known to trigger non-specific tissue damage, especially in
the gastrointestinal (GI) tract. This damage leads to release of danger signals ,
such as, pro-inflammatory cytokines (TNF, IL-1, and IL-6 (18)), chemokines and
chemokine receptors (19), by the host tissues, and increased expression of costimulatory molecules on host APCs (11). Specifically, GI injury due to
conditioning regimen causes systemic release of commensal gut bacteria and
subsequent increase in lipopolysaccharide (LPS) and pathogen associ ated
molecular proteins (PAMPs). This increase in danger signals, augments antigen
presentation by host APC resulting in strong activation, proliferation, and
differentiation of donor T-cells that play one of the most important role in GvHD related morbidity in leukemia patients (20). The release of danger signals also
causes innate immune cell activation which ultimately results in increased
production of pro-inflammatory cytokines and tissue inflammation (17). GvHD
manifests as skin rash and progresses towards other body organs, mainly, lung,
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liver, gut, and skin. Therefore, targeted treatment, as opposed to global
immunosuppression, against this host inflammation and non-specific tissue
damage caused by conditioning regimen could potentially reduce GvHD while
maintaining the GvL activity.

1.2.2 Alloreactivity in Graft versus Host Disease

GvHD is largely mediated by alloreactive donor T -cells. During T-cell
development in thymus, immature T-cells undergo positive and negative
selection. Positive selection refers to when T-cells that adequately recognize
self-peptide self-MHC complex are chosen for further differentiation, while
negative selection is when self-recognizing autoimmune T-cells are signaled to
die. Alloreactivity refers to when the T-cells can recognize peptide and
allogeneic MHC complexes that were not encountered during thymic selection
(10). Alloreactive T-cells have been widely studied in the context of GvHD and
whether their elimination could reduce incidence of GvHD (21). However,
alloreactivity is important for development of both, GvHD and GvL effect , in
allogeneic HSCT (22). In a HLA-matched HSCT, alloantigens that mediate GvHD
and GvL are called minor histocompatibility antigens (miHA). MiHAs are cell surface

proteins

that

are

associated

with

MHCs.

Single

nucleotide

polymorphisms (SNPs) can translate into differences in miHAs between HLAmatched donor-host pair, especially matched unrelated donors, and are
increasingly being recognized for their therapeutic potential in leukemia (23, 24).
However, whether miHA differences translate into graft versus host disease is
debatable (25).
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1.2.3 Existing Therapies for Graft Versus Host Disease

One of the crucial aspects of therapeutic development for GvHD is
preserving the GvL effect of the allogeneic HSCT. One of the widely-employed
preventive therapies is reducing the intensity of myeloablative conditioning
regimen given to the patient. While reduced intensity conditioning regimen
considerably reduces GvHD symptoms, it also increases the burden on the donor
HSCs for eliminating leukemia. Multiple studies have shown that reduced
intensity conditioning fails to improve long-term survival due to high rate of
leukemia relapse (17, 26). Another important step in development of GvHD is
homing of T-cells to the site of tissue damage via chemokine signaling. Targeting
alloreactive T-cell homing via chemokine-ligand antagonists such as CCR5
antagonists, have shown to lessen the damage to the target organs (27).
However,

these

therapies

may

also

interfere

with

recruitment

of

immunosuppressive T-cell subsets (17, 28). Th-1, Th-2, and Th-17 type
cytokines play variable and important roles in GvHD development. Cytokine
modulators such as Alpha-1 antitrypsin and cytokine IL-22 are currently under
clinical trials as therapy for their protective role in GvHD (29). Many other
cytokines, such as IFNγ, TNF, IL-6, and IL-23 or their modulators are being
studied using murine models of GvHD (17, 18). Additionally, JAK/STAT inhibitors
have also shown promise as treatment therapy for GvHD (30). JAK-STAT
signaling pathway is downstream of cytokine-receptor binding, and causes
activation of antigen presenting cells (APCs), which in turn results in higher APC
and T-cell interaction. Therefore, preventing donor APC activation by JAK/STAT
inhibition could prevent GvHD without reducing the GvL activity. Lastly, there
8

has been increasing interest in immunomodulatory cell therapies for GvHD.
Invariant Natural Killer T-cells (iNKT cells) (31), myeloid-derived suppressor
cells (MDSCs) ((32, 33), and their various subsets, are being investigated in
mouse models of GvHD for their immunosuppressive role through cytotoxic Tcell interaction or production of immunosuppressive cytokines.

These are few among a large number of therapies that are currently being
studied for preventing GvHD development at various points in the signaling
cascade. However, we wanted to determine the effect of blocking initial
inflammation by using anti-inflammatory and anti-oxidative agent, and if it could
stop the signaling cascade from progressing to GvHD related end organ damage
and/or death.

1.3 Bilirubin Nanoparticle

Bilirubin is a linear tetrapyrrole molecule, naturally found in human blood.
It is an orange-yellow pigment, found in the liver and is produced as an end
product of heme catabolism. At the end of a red blood cells’ (RBC) life time, they
undergo lysis. In this process, hemoglobin gets degraded and the heme part gets
oxidized by an enzyme called heme oxygenase, forming biliverdin. Biliverdin is
a greenish molecule that gets reduced by an enzyme called biliverdin reductase
(BVRA), to form bilirubin. This process occurs in the reticuloendothelial cells of
the liver, spleen and bone marrow. This bilirubin is ultimately carried to the liver
via blood, where it performs various biological functions. Bilirubin is known for
its anti-inflammatory and antioxidant properties and has been inversely
correlated with cardiovascular risk (34). Bilirubin quenches reactive oxygen
9

species (ROS) and gets converted into biliverdin, which is converted back to
bilirubin through BVRA enzyme ((35) Figure 1). This recycling property, makes
bilirubin a very powerful protectant against cellular oxidative damage. Higher
bilirubin levels in adults are correlated with a number of health benefits such as
lower prevalence of, non-alcoholic fatty liver disease, cardiovascular disease
development, colorectal cancer, and ischemia–reperfusion injury after liver
transplantation among many others (36).

Figure 1- Mechanism of production and anti-oxidative activity of Bilirubin
(inspired from Bara n a no et al. (35)). Heme part of the hemoglobin get oxidized
to produce biliverdin, by an enzyme called heme oxygenase (HO) anchored on
the endoplasmic reticulum (ER). With the help of an enzyme called biliverdin
reductase (BVRA), biliverdin gets reduced to form bilirubin. BVRA regenerates
bilirubin that gets oxidized to form biliverdin upon quenching of membrane bound
10

reactive oxygen species (ROS). This cycle enables low concentration bilirub in
to quench up to 10,000 fold higher concentrations of oxidants.

Despite its well-known anti-inflammatory and anti-oxidative properties
Bilirubin is rendered difficult for clinical use because of its water insolubility. In
an attempt to harness the therapeutic properties of bilirubin, investigators at
Korea Institute of Advanced Science and Technology ( KIAST) South Korea,
recently developed a water-soluble conjugate of bilirubin and polyethylene glycol
(PEG), known as the bilirubin nanoparticle (BRNP). PEG forms a stable amide
bond with bilirubin to form PEGylated bilirubin (PEG-BR). Since bilirubin is a
lipophile and PEG is a hydrophile, the end product PEG-BR is an amphiphile,
which self-assembles to form a micelle-like structure or bilirubin nanoparticle.
This nanoparticle is about a 100 nm in size in freeze -dried state and retains the
properties of bilirubin while being water -soluble. Upon stimulation with light,
BRNP turns into photoisomer of bilirubin. Also and more i mportantly, upon
oxidative stress such as with ROS, BRNP turns into biliverdin or oxidized
fragments of bilirubin.
Recent studies by investigators at KAIST, have shown that due to it’s freeradical scavenging properties, BRNP selectively accumulates at the site of
inflammation and tissue damage in dextran sodium sulfate induced colitis in
murine model (37). In mice, pre-treated with BRNP, pathological changes
associated with ischemic reperfusion were found to be significantly less as
compared to mice that were treated with vehicle (38). Similarly, BRNP treatment
showed significant benefits in mouse models of other infl ammatory conditions,
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such as asthma (39), pancreatic islet xenotransplantation (40), and even as a
conjugate for anti-cancer therapy (41, 42).

1.4 Hypothesis

Therefore, we hypothesize that, BRNP treatment can reduce graft versus
host disease due to its beneficial anti-inflammatory properties which act against
tissue damage and inflammation in murine GvHD model.

12

Chapter 2- Materials and Methods

2.1 Mice

All animal experiments were conducted per The University of Texas MD
Anderson Cancer Center’s Institutional Animal Care and Use Committee
guidelines. Six- to eight- week old female, C57/B6J and Balb/c, mice were
purchased from Jackson Laboratories (Bar Harbor, ME ).

2.2 Hematopoietic Stem Cell Transplantation

On day 0, 10- to 15- week old female Balb/cJ mice were given 800 cGy of
Total Body Irradiation (TBI). On Day 1, age-matched donor female C57/B6J mice
were dissected to obtain spleen and hind limb bones (femurs and tibiae).
Spleens were pooled together in sterile 1X PBS and gently mashed. The
suspension was strained through a 70 μm cell strainer to obtain single cell
suspension. Bone marrow cells were obtained by flushing the bones, with 1X
PBS through a 27G needle, until they appeared white. Bone marrow cells were
also similarly strained through 70 μm cell strainer to obtain a single cell
suspension. Both, spleen and bone marrow lymphocytes (without red b lood
cells) were counted on hemocytometer.

For our first model, we transplanted 1 x 10 7 RBC lysed splenocytes in
mice, while the negative control group received 5 x 10 6 BM cells only. These
mice transplanted with splenocytes, either received a single dose of 10 mg/kg
BRNP or equivalent volume of vehicle (1X PBS) on day 0.
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For our second model, we transplanted 1 x 10 6 conventional T-cells (CD4 +
and CD8 + T-cells or Tcons) along with 4 x 10 6 BM cells. Starting from day 0,
these mice received 3 doses of 10 mg/kg BRNP or equivalent volume of vehicle
(1X PBS), every two days. The negative control mice received 4 x 10 6 BM cells
only. Tcons were purified using MACS ® Cell Separation technique (Miltenyi
Biotec). For isolating CD4 + and CD8 + T-cells, 5 x 10 8 splenocytes from donor
mice were incubated with anti-mouse CD4 MicroBeads (clone: L3T4, cat no. 130117-043) and anti-mouse CD8 MicroBeads (clone: Ly2, cat no. 130-117-044) in
magnetic associated cell sorting (MACS) buffer (PBS, pH 7.2, 0.5% human
serum albumin-HSA (Sigma Life Science, cat. no. SRP6182)), and 2 mM EDTA
(USB- Thermo Fisher, cat. no. 15694) for 20 minutes in dark at room
temperature. Subsequently, CD4 + and CD8 + T-cells were isolated using LS
column (Miltenyi Biotec, cat. no. 130-052-401) according to the manufacturer’s
specified protocol. The isolated Tcons were washed and resuspended in 1X PBS
for counting and subsequent transplantation in mice.

For our third model, 5 x 10 6 splenocytes and 5 x 10 6 bone marrow cells
were transplanted intravenously. The negative control group received 5 x 10 6
bone marrow cells only. From day 0 to day 4, mice received 5 daily doses of 10
mg/kg BRNP or equivalent volume of vehicle (1X PBS) intravenously.

2.3 Bilirubin Nanoparticle

Lyophilized BRNP was generously provided by Dr. Sangyong Jon and his
laboratory at the Korea Advanced Institute of Science and Technology (KAIST),
South Korea. Five milligrams of lyophilized BRNP was dissolved in 1 ml of 1X
14

PBS. This solution was stored at 4 o C, protected from light, and used within 7
days.

2.4 Flow Cytometry Analysis

Splenocytes and bone marrow cells that were used for transplant, were
stained with anti-mouse, CD3ε (BioLegend, cat no. 100306), B220 (BD
Pharmingen™, cat no. 553093), CD4 (BD Pharmingen™, cat no. 558107), and
CD8 (BD Horizon™, cat no. 563068) antibodies for 30 minutes in dark. The cells
were then washed with 1X PBS, fixed in 2% paraformaldehyde, and stored at
4 o C until flow acquisition. The samples were acquired using Canto II Cell
Analyzer (Beckton, Dickinson and Company, Franklin Lakes, NJ), and FlowJo
version 10.3 (Tree Star, Ashland, OR) was used for analysis.

2.5 Clinical Graft Versus Host Disease Assessment

Mice were scored for clinical GvHD, by using a previously established
scoring system by Cooke et al.(43). Mice were scored from 0-2 for, Weight (0:
<10% loss, 1: ≥10% <25%, 2: ≥25%), Fur (0: normal, 1: mild to moderate, 2:
severe ruffling), Posture (0: normal, 1: kyphosis at rest, 2: kyphosis impairing
movement), Activity (0: normal, 1: stationary 50% of the t ime, 2: stationary
unless stimulated), Skin (0: normal, 1: scaling paws or tails, 2: lesions). In
addition, all the treatment groups were also monitored for survival, and sacrificed
if they seemed inactive or non-responsive to stimuli.
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2.6 Pathological Graft Versus Host Disease

On day 0, 10-15 week old female Balb/c mice received 800 cGy TBI. On
day 1, the donor C57/B6 mice were sacrificed to obtain their splenocytes and
BM cells. 5 x 10 6 whole splenocytes and 5 x 10 6 bone marrow cells were
transplanted intravenously to the BRNP treated and the vehicle groups. The
negative control group received 5 x 10 6 bone marrow cells only. From day 0 (4
hours after transplantation) to day 4, the mice received 5 daily doses of 10 mg/kg
BRNP or equivalent volume of vehicle (1X PBS) intravenously. These mice were
sacrificed on day 8 after transplantation, and their blood, spleen, liver, lung, and
skin were harvested for other downstream exper iments- serum cytokine analysis
and histopathology.

2.7 Serum Cytokine Quantification

Blood for each individual mouse was collected by retro-orbital vein
puncture. Tubes with blood were centrifuged at 600g for 5 minutes. Serum
supernatant was collected and stored at -80 o C until used for analysis. BD™
Cytometric Bead Array (CBA) (cat no. 560485) was used to determine the serum
cytokine concentrations of Th1, Th2, and Th17 type cytokines, namely- IL2, IL4, IL-6, IFN-γ, TNF, IL-17A, and IL-10 proteins. Sera for all the treatment group
mice was diluted 1:4 in assay diluent, incubated with mixed capture beads and
subsequently washed according to the manufacturer’s instructions. The samples
were acquired using LSR Fortessa Cell Analyzer (Beckton, Dickinson and
Company, Franklin Lakes, NJ), and FlowJo version 10.3 (Tree Star, Ashland,
OR) was used for analysis.
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2.8 Histopathology

Mouse organs, namely- skin (from dorsal region), liver (one lobe), lung
(one lobe), small intestine (duodenum), and spleen, were fixed in 10% buffered
formalin, and submitted to Research Histology Core Laboratory at The University
of Texas MD Anderson Cancer Center, for haematoxylin and eosin staining. The
sample slides were then evaluated by a pathologist who scored the tissues for
inflammation and GvHD associated damage for each organ.

2.9 Statistical Analysis

All statistical analyses were performed using GraphPad Prism Software
version 7.00 (La Jolla, California) for Windows. Data sets were analyzed using
Mann-Whitney U Test with confidence level: 95%, and p values for comparisons
between groups were determined. For survival analysis, Log-rank (Mantel-Cox)
survival test was used. A p value less than 0.05 was considered to be statistically
significant.
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Chapter 3- Results and Analysis

3.1 Mouse Model of Graft Versus Host Disease

The first step to determine the anti-inflammatory and anti-oxidative effects
of BRNP, was to establish a simple and reproducible murine model for acute
GvHD. We chose HLA mismatch model of H-2 b C57BL/6 mice as donors and H2 d Balb/c mice as recipients. To determine optimal transplant dose, we
shortlisted different published models with their respective outcomes, as
outlined in Table 1 below.

Table 1- Shortlist of published murine GvHD models- detailed for their
transplant dose, radiation dose, and outcome
b

d

HLA Mismatch model- C57BL6 (H2 ) → Balb/c (H2 )
Cell type and

Conditioning

dose

Regimen
7

2 x 10 Whole

700 cGy

6

TCD-BM 2 doses
400 cGy
6
and 1 x 10 Tcons
6
5 x 10 BM and 5 800 cGy
6

x 10 Splenocytes
6
25 x 10 GM-CSF 900 cGy

Reference

Survival between

Margalit et al.(44)

day 10-50

Splenocytes
5 x 10

Outcome

of

Systemic

Schneidawind et al.

disease by Day

(31) and Griesenauer

7-30

et al. (45)

Survival between

Im et al. (46) and

day 10-40

Wang et al.(47)

Systemic

Kuns et al. (48)

mobilized

disease by day

splenocytes

5-14
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We attempted three models with or without BRNP treatment. The first
murine model (Margalit et al. (44); Table 1) received 800 cGy radiation on day
0, and a single dose of 10 mg/kg BRNP (optimized by our collaborating
investigators (38)) 4 hours after radiation (Figure 2a). On day 1, the vehicle
control (n=10) and the BRNP test group (n=10) of mice were transplanted with
1 x 10 7 RBC lysed splenocytes and 5 x 10 6 BM cells, whereas the negative
control group (n=5) received 5 x 10 6 BM cells only. Mice were monitored for their
weight and GvHD score every two days or until their death/ recommended
euthanasia. Euthanasia was recommended at very low or no activity and/or
extreme (>30%) weight loss.

The mice in this experimental group were highly inactive and lost more
than 25% of their initial weight within 8 days from transplantation (Figure 2b).
We observed that mice were severely kyphotic and lethargic, owing to the high
dose of RBC lysed splenocytes (Figure 2c). Within 13 days, 100% of both the
vehicle control and the BRNP test groups had died (Figure 2d). For our next
experiment, we concluded that, donor cell dose should be lowered and BRNP
dose should be increased.
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Figure 2- Clinical GvHD outcome of the first strategy of murine GvHD
model. (A)- Vehicle control group (n=10), BRNP test group (n=10) and negative
control group (n=5) received 800 cGy TBI on day 0. On day 1, vehicle control
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group and BRNP treated group were transplanted with 1 x 10 7 RBC lysed
splenocytes, while the negative control group was transplanted with 5 x 10 6 BM
cells only. BRNP test group received a single dose of 10 mg/ kg, 4 hours after
TBI on day 0, while the vehicle control group received vehicle (1X PBS) I.V.
injection. There were no significant differences between the BRNP + BM C ells +
Splenocytes (test) group versus the BM Cells + Splenocytes (vehicle) group in
terms of (B)- weight change, (C)- GvHD score, and (D)- Survival. “ns” stands for
non-significant. p value was determined using Mann Whitney U Test for weight
and GvHD score, and Mantel Cox Survival Test for survival

For our second strategy (Schneidawind et al. and Griesenauer et al. (31,
45); Table 1), we performed TBI of 800 cGy on day 0, and 4 hours later the mice
were given their first dose of 10 mg/kg BRNP or equivalent volume of vehicle
(1XPBS). On day 1, the recipient mice were transplanted with 1 x 10 6
conventional T-cells (Tcons) instead of whole splenocytes, along with 4 x 10 6
BM cells. On day 2 and day 4, the mice received additional dose of 10 mg/kg
BRNP or equivalent volume of vehicle (1XPBS) (Figure 3a). All the treatment
groups were monitored for their weight, GvHD score, and survival, f or 2 months
or until, their death/recommended euthanasia. Despite no significant change in
weight loss (Figure 3b), this experiment was successful as we observed
significantly lower clinical GvHD scores in the BRNP treated group (Figure 3c)
which translated into significantly better survival outcome (F igure 3d).
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60

Figure 3- Clinical GvHD outcome of the second strategy of murine GvHD
model. (A)- Vehicle group (n=9) and the BRNP treated group (n=9) mice were
given 800 cGy TBI on day 0, and transplanted with 1 x 10 6 Tcons and 4 x 10 6
BM cells from C57/B6 mice on day 1. On day 0, 2, and 4, the BRNP treated
group mice were i.v. treated with 10 mg/kg dose of BRNP, while the vehicle
control group received equivalent volume of 1X PBS. The negative control group
(n=5) mice received 4 x 10 6 BM cells only. No significant changes between the
BRNP + BM Cells + Splenocytes and BM Cells + Splenocytes groups were seen
in (B)- Weight, however, BRNP + BM Cells + Splenocytes group of mice has
significantly lower (C) GvHD score (p<0.0001, Mann Whitney U Test), which
translated into better (D) survival (p=0.0322; Mantel-Cox Survival Test). The
median survival for BRNP test group at day 60 was 65% as compared with
vehicle control in which only 11% of the mice survived. Error bars represent
standard error of mean.

In other studies by our collaborating investigators they have reported that
doses as high as 150 mg/kg BRNP (15-fold higher than our current dose) are
non-toxic to mice (10 mg/kg). Therefore for our next strategy, we decided to
increase the number of BRNP injections in order to maximize the antiinflammatory and anti-oxidative activity against GvHD. While several factors
such as radiation dose, donor recipient strains, and p athogens associated with
colony influence the GvHD outcome, the most important factor is the T-cell
dosage (49). To test the efficacy of BRNP as an anti-inflammatory molecule, we
wanted to establish a rather simplified murine model with reliable GvHD
outcome.
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3.2 BRNP Treatment Can Increase Survival in Murine Acute Graft Versus Host
Disease Model

We tested the anti-inflammatory and anti-oxidative benefits of BRNP
treatment in murine acute GvHD by using our third model (Im et al. and Wang et
al. (46, 47); Table 1), which was consistently reproducible. For our third strategy,
we gave 800 cGy TBI to the recipient mice on day 0, followed by intravenous
administered of 10 mg/kg BRNP, 4 hours later . On day 1, we transplanted 5 x
10 6 whole splenocytes and 5 x 10 6 BM cells in the vehicle control and the BRNP
test groups, whereas the negative control group was transplanted with 5 x 10 6
BM cells only. BRNP test group mice were given 5 daily doses of 10 mg/kg
intravenous BRNP from day 0-4 while the vehicle control group similarly received
vehicle (1X PBS) injections (Figure 4a).

Similar to our second strategy for HSCT, we observed that after an initial
weight loss within the first week (Figure 4b) for all the three treatment groups,
only the BRNP treated group and the negative control mice swiftly recovered.
The vehicle control group continued to show faster weight loss till around day
13 and a delayed recovery as compared with BRNP treated or the negative
control groups. We observed that while the BRNP treated mice continued to
maintain their weight between 90-100% of their initial weight, the vehicle control
mice kept getting significantly worse (p=0.0001; Mann Whitney U Test) after their
initial recovery. Similar to the weight loss trend, we observed significantly lower
GvHD score in BRNP treated mice as compared to the vehicle control group
(p=0.0003, Mann Whitney U Test; Figure 4c). Despite being a subjective method

24

of scoring, GvHD score provides a crucial measurement of clinical GvHD
development in mouse model. The initial peak in GvHD score at around day 15
for vehicle control mice, can be partly attributed to weight loss due to gut toxicity
caused by radiation treatment. The BRNP treated group, howev er, did not seem
to develop a similar extent of radiation toxicity, as their GvHD score did not
increase. Although the vehicle control mice did recover from the initial weight
loss, they quickly started to show clinical symptoms again at around day 20. At
the same time, the BRNP treated group also showed a slight increment in their
GvHD score, but it was still less than their vehicle control counterparts. While
the untreated mice, continued to show symptoms through their lifetime, the
BRNP treated group, recovered around day 30, and did not show GvHD
symptoms anymore. Lower GvHD score and weight loss, translated into
significantly higher survival (p=0.0001; Log-rank (Mantel-Cox) survival test) in
BRNP treated mice, as compared with the vehicle control mice (Figure 4d). At
day 60, 100% of the BRNP treated mice had survived, while for the vehicle
control group, only 20% of the mice survived.

We observed that the survival of BRNP treated mice in our thi rd model of
acute GvHD (Figure 4d; 100% mice survived until day 60), is better than their
survival in second strategy (Figure 3d; 65% mice survived until day 60). This
could be attributed to either change in the transplantation strategy, or to the
increase in number of BRNP injections. However, in both the strategies, 11%
and 20% of the vehicle control mice survived by day 60, indicating that both
strategies were capable of forming similar extent of GvHD. Therefore, increasing
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the dose of BRNP, may have led to the higher survival in BRNP test group,
indicating the potential beneficial effects of BRNP against GvHD development.
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60

Figure 4- Clinical GvHD outcome of the third strategy of murine GvHD
model. Shown here is cumulative data from N=2 independent experiment s. (A)Vehicle control group (n=10) and the BRNP test group (n=10) mice were given
800 cGy TBI on day 0, and transplanted with 5 x 10 6 BM cells and 5 x 10 6
splenocytes from C57/B6 mice on day 1. On day 0 to 4, the BRNP test group
mice were given 10 mg/kg intravenous dose of BRNP, while the vehicle control
group received similar vehicle (1X PBS) injections. The negative control group
(n=5) mice received 5 x 10 6 BM cells only. As compared with BM Cells +
Splenocytes group, the BRNP + BM Cells + Splenocytes group showed
significantly lower (B)- Weight loss (*p<0.0001, Mann Whitney U Test) (C) GvHD
score (*p<0.0001, Mann Whitney U Test), which translated into better (D)
survival (p=0.0003; Mantel-Cox Survival Test). Error bars represent standard
error of mean. *p<0.0001 (Mann Whitney U Test) between BRNP + BM Cells +
Splenocytes and BM Cells + Splenocytes groups. #p=0.0208 (Mann Whitney U
Test) between BRNP + BM Cells + Splenocytes and BM Cells only groups.
&p=0.0003 (Mantel-Cox Survival Test) between BRNP + BM Cells + Splenocytes
and BM Cells + Splenocytes groups.

27

3.3 BRNP Treatment Can Reduce Pathological Symptoms of Acute Graft Versus
Host Disease

To determine the protective role of BRNP treatment on pathological
symptoms of acute GvHD, we performed histopathological analyses on GvHD
target organs such as the liver, lung, gastrointestinal tract (GI), and skin. We
performed SCT on three treatment groups, with our previously optimized third
strategy, and on day 8 we sacrificed the mice to collect their GvHD target organs
along with blood and spleen.

We performed cytokine bead array on blood sera collected from all the
treatment group mice. Serum levels for pro-inflammatory cytokine IFNγ (Figure
5a) and TNF (Figure 5b) were trending lower in the BRNP test mice (n=5) as
compared to vehicle control mice (n=4), however they were not found to be
significantly different. Higher serum levels of these pro-inflammatory cytokines
are associated with higher organ damage which result in more severe onset of
acute GvHD (18). We also analyzed other Th1, Th2, Th17 cytokines such as IL2,
IL-4, IL-6, IL-17A, and IL-10. However, due to limitations in the cytokine bead
array, values lower than 20 pg/ml are not accurately detectable. And therefore,
we were unable to measure the serum cytokine levels of these proteins in our
treatment groups.

A previous GvHD study showed that, transplant engraftment in mice, with
4 x 10 6 MHC-mismatch splenocytes after 800 cGy radiation, happens within 6
days after transplant (50). Another study with different acute GvHD mouse model
shows that histopathological changes are most apparent at around 7 days after
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transplantation (compared between day 5, day 7, and day 21) (51). Indeed,
within 24 hours after HSCT in mice, the donor T -cells migrate to secondary
lymphoid organs for alloantigen priming before migrating to the GvHD target
organs (49). Based on these studies, we justified sacrificing the three treatment
groups, along with naïve control, on 8 th day after transplantation.

Manifestation of skin inflammation and rash is one of the first symptoms
of GvHD development after allogeneic transplantation. In agreement with our
hypothesis, we observed significantly lower inflammatory cell infiltration in skin
of the BRNP treated mice as compared with vehicle control (Figure 6, Figure
7a). Lung and liver damage is one of the hallmarks of GvHD development. We
observed significantly less inflammation in lung (Figure 6, Figure 7b) and liver
(Figure 6, Figure 7c) in BRNP treated mice when compared with vehicle control
mice. Lastly, the duodenum part of the gastrointestinal tract shows significantly
lesser necrosis in BRNP treated mice as compared to the vehicle control (Figure
6, Figure 7d), thus proving our hypothesis that BRNP treatment can reduce
pathological symptoms of GvHD.

Quantitative evaluation of GvHD associated organ damage shows
significantly lower lymphocyte infiltration in hair follicles (Figure 7a; p=0.0079;
Mann-Whitney Test) indicating lower skin damage in mice treated with BRNP.
We also observed significantly lower perivascular inflammation in lung (Figure
7b), and central vein inflammation in liver (Figure 7c). GI tract damage is one of
the hallmarks of GvHD, and we found significantly lower single -cell necrosis in
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the BRNP treated group as compared with vehicle control. BRNP treated mice
showed close similarities with the negative control group in all histology scores.
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Figure 5- Serum levels of pro-inflammatory cytokines IFNγ and TNFα.
Cytokine analysis shows a trending decrease in pro-inflammatory cytokines (A)IFNγ and (B)- TNF in the blood serum collected on day 8 post transplantation.
Each dot represents individual mouse for all treatment groups. The error bars
represent standard deviation. ns= Non-significant (Mann- Whitney U Test).
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Figure 6- BRNP treatment can reduce GvHD associated tissue damage,
such as lymphocyte infiltration, inflammation, and necrosis. Shown here are
representative images of hematoxylin and eosin (H&E) staining for different
GvHD target organs, namely, liver, lung, skin, and GI. Skin- In BM Cells +
Splenocytes panel, green arrow shows an example of inflammatory cell
infiltration, and the green arrow head shows an example of single-cell necrosis,
which is significantly less in the BRNP treated mice. Lung - Donor (naïve control)
and the BRNP treated mice show the least inflammation, as compared to the BM
Cells + Splenocytes and BM Cells only group. Liver- Symbol P in the liver panel
for all the treatment groups represents portal tract. Compared with BM Cells +
Splenocytes group, the BRNP treated mice show fewer inflammatory cells, w hile
donor mouse shows normal portal vein with no inflammation. GI - Red arrows
show single-cell necrosis in the glandular epithelium and the yellow asterisk (*)
show necrotic cells in crypt lumen. BRNP treated mice showed lesser GI singlecell necrosis as compared to BM Cells + Splenocytes group.
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Figure 7- BRNP treatment can reduce pathological symptoms of acute
GvHD in mice. Shown here is a quantitative evaluation of histopathology of
acute GvHD performed by a board-certified pathologist. Pathological symptoms
in different GvHD target organs such as (A) infiltration of hair follicles in skin,
(B) perivascular inflammation, peribronchiolar inflammation, and interstitial
pneumonia in lungs, (C) portal vein inflammation, central vein inflammation, and
necrotic foci in liver, and (D) single cell necrosis and necrotic cells in crypt lumen
of the GI. Histology ratio on y-axis for inflammatory conditions was measured by
dividing the number of affected areas with total number of the areas observed
under a 40X objective. Interstitial pneumonia scoring for lungs was done by
evaluating the percentage of affected area under 10X objective a nd assigning a
score from 1-4 with 4 being the most affected (Scoring: 1=<25%, 2=>25% to
<50%, 3=>50% to <75%, 4=>75%). Similarly for liver, the number of necrotic foci
counted were normalized with the number of evaluated areas observed under
10X objective. Lastly, single cell necrosis or necrotic cells in crypt lumen for GI,
were quantified by normalizing the counted number of necrotic cells with the
number of areas evaluated. Dot-plots for all the treatment groups were plotted
along with a single donor used as naïve histopathological control and statistics
were performed using Mann-Whitney U Test.
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Chapter 4- Discussion and Future Direction

Most therapies such as steroids that are currently in clinic as first line
treatment for GvHD are globally immunosuppressive, which leads to compromise
in the GvL effect of the allogeneic HSCT. Other prophylactic therapies such as
reduced conditioning regimen are good for reducing GvHD sympt oms, however
because of being non-myeloablative, it comes with a higher risk of infections
and/or leukemia relapse (26). Several studies continue to explore and
understand the immune cell interactions that ha ppen after the allogeneic HSCT
to identify potential therapeutic targets for GvHD. There have been a few studies
that look at the role of anti-oxidative agents, such as hydrogen therapy (52),
green

tea

extracts

(53),

and

ROS

scavenging

compounds

such

as

cyclopentylamino carboxymethylthiazolylindole (NecroX-7) (46) as treatment for
GvHD related organ damage using murine models of GvHD. However, there is a
critical unmet need for clinically relevant, scalable, and non-toxic therapies for
GvHD that do not affect the GvL outcome.

Bilirubin is a very effective and powerful antioxidant pigment found
naturally in mammalian blood serum. Several human and mouse studies show
that higher bilirubin level in blood serum is associated with protection against,
cardiovascular diseases, non-alcoholic fatty liver disease, colorectal cancer, and
ischemia–reperfusion injury after liver transplantation (36). Bilirubin has shown
to be an effective antioxidant immunomodulator as treatment for experimental
autoimmune encephalomyelitis (54, 55). However, elevated blood serum levels
of bilirubin can be toxic due to its water insolubility. Hyperbilirubinemia may
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indicate liver damage and can be neurotoxic in new born infants. More
importantly, elevated bilirubin levels are found in patients that develop acut e
GvHD after allogeneic HSCT.

To maximize the therapeutic potential and reduce the toxicity of bilirubin,
investigators at KAIST conjugated polyethylene glycol with bilirubin, which
resulted into an amphiphilic molecule that self-assembles to form stable, nontoxic (at concentration as high as 150 mg/kg) , and water soluble bilirubin
nanoparticles. Polyethylene glycol is an FDA approved active ingredient .
Conjugation with polyethylene glycol or PEGylation is used to improve the
pharmacokinetic activity of various FDA approved drugs such as peginterferon
alfa-2a for hepatitis C treatment (56). However, conjugation with PEG, especially
near active site of the drug, may cause decrease in the drug activity in some
cases (57). PEGylation of bilirubin has been shown to not affect the
characteristic antioxidative and light sensitive properties of bilirubin, in both in
vitro and in vivo experiments. Moreover, BRNP treatment has shown benefits in
various mouse models of inflammatory diseases (37-41).

In this study, we looked at clinical and pathological benefits of BRNP as
a prophylactic therapy for GvHD. Through our pre-clinical mouse model of GvHD
we show that five daily intravenous doses of 10 mg/kg BRNP treatment
significantly reduces, GvHD symptoms, associated weight-loss, and improves
overall survival. Pathological damage associated with the onset of GvHD was
also found to be significantly less in skin, liver, lung, and GI. We found
significantly lesser lymphocyte infiltration and inflammation in these organs ,
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which may have contributed to the higher overall survival. We believe that BRNP
treatment was able to reduce the initial non -specific tissue damage associated
with conditioning regimen and continued to reduce tissue damage after HSCT.
Lower tissue damage could translate into reduced antigen presentation to donor
cytotoxic T-cells, which ultimately lessens the cytokine production and endorgan damage. We performed serum cytokine analysis, and saw a trend towards
lower inflammatory cytokine production in the BRNP treated G vHD mice. Overall,
our results show that prophylactic BRNP treatment in mouse GvHD model, is
beneficial in reducing the symptoms and improving overall survival .

In future studies, we want to assess a treatment model of BRNP in
reducing GvHD symptoms and improving overall survival. Through our mouse
GvHD model, we plan to evaluate the role of post-transplantation BRNP
treatment in alleviating GvHD symptoms without affecting the GVL activity of
HSCT. In the treatment model, it would also be interesting to analyze
immunomodulatory effects of BRNP by performing flow cytometry analysis for
various immune cells and subsets, on the GvHD target organs.

Bilirubin nanoparticles dissociate into water-soluble photoisomers of
bilirubin upon light (λ= 450 nm or 650 nm) stimulation (41). BRNP has also been
shown to accumulate specifically at the site of tissue damage in a mouse colitis
model, (37). Utilizing these properties of the nanoparticles, our collaborating
investigators at KAIST, have successfully tested BRNP as a nano drug -carrier
for anti-cancer therapy (42). Therefore, after establishing BRNP in a treatment
model for GvHD, a future extension of this study would be to evaluate BRNP as

37

a drug conjugate for existing therapies for GvHD. Our first step would be to check
for the accumulation site of the BRNP-drug conjugate in the mouse model, and
test whether BRNP can successfully transport the drug to the site of organ
damage. Eventually, we would compare clinical and pathological symptoms of
GvHD along with overall survival using our mouse GvHD model treated with
BRNP-drug conjugate and BRNP alone. Our hypothesis is t hat BRNP-drug
conjugate can selectively reduce tissue damage, thereby reducing the global
toxicity of the drug and improving the GvHD outcome.
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